Kahn Clare 4

What Happened

• Clare Kahn, a director of Stoke Therapeutics (STOK), was granted a derivative award of 30,782 shares on April 3, 2026. The reported acquisition price is $0.00 (derivative award/option), so no cash was paid at grant.

Key Details

• Transaction date: April 3, 2026; Filing posted: April 7, 2026.
• Shares/units granted: 30,782 (derivative award; reported at $0.00).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The option award vests as to 1/12 of the total award quarterly on the first calendar day of each July, October, January, and April, with the first tranche vesting July 1, 2026 — i.e., vesting over 12 quarters (about 3 years), subject to continued service.
• No 10b5-1 plan, tax-withholding, or late-filing flag indicated in the supplied record.

Context

• This was a grant/award (A) — not an open-market purchase or sale. Grants are common as compensation for directors and employees and do not by themselves indicate buying or selling conviction. As a derivative (option) award, value to the recipient depends on future stock performance and the vesting schedule.